drugset / Trial / NCT00913432

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

NCT00913432

Phase 2 Completed 20 enrolled AB Science
RandomizedParallel-groupOpen-labelTreatment

Summary

A 12-week with possible extension, phase II study to compare efficacy and safety of masitinib at 3 and 6 mg/kg/day in combination with methotrexate, in treatment of patients with active rheumatoid arthritis refractory to standard treatments.

Timeline

Start
2007-03
Primary completion
2009-06
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Masitinib Small molecule 3 mg/kg Oral
Subject Masitinib Small molecule 6 mg/kg Oral

Indications